Indications for use
Advanced unresectable or metastatic prostate cancer requiring testosterone suppression:
- antiandrogen therapy for inoperable prostate cancer;
- reduction in the severity of hyperandrogenism observed at the beginning of therapy with gonadotropin-releasing hormone (GnRH) agonists;
- relief of hot flashes in patients with prostate cancer receiving GnRH agonist therapy or in patients who have undergone orchiectomy.
Increased libido in sexual disorders.
Contraindications for use
In the treatment of advanced inoperable or metastatic prostate cancer, if it is necessary to suppress the action of testosterone:
- Hypersensitivity to cyproterone or other components of the drug.
- Liver diseases (including Dubin-Johnson syndrome, Rotor syndrome), liver tumors in history or currently (with the exception of prostate cancer metastases to the liver).
- Cachexia (except for cachexia in prostate cancer).
- Severe chronic depression.
- Thrombosis and thromboembolism at present.
- Presence of meningioma currently or in history.
- Children and adolescents under 18 years of age.
